Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8637-8648
DOI: 10.1111/dom.71061 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 06.07.2026. Verfasst von Mengyun Lei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of tubeless hybrid closed‐loop (HCL) systems in type 1 diabetes (T1D).
Methods
We searched Web of Science, PubMed, Scopus, and Embase from inception to April 1 st , 2026 for randomized controlled trials (RCTs) comparing tubeless HCL systems with standard care (SC; sensor‐augmented pumps [SAP] or multiple daily injections [MDI] + continuous glucose monitoring [CGM]). Primary efficacy outcomes were time in range of 3.9–10.0 mmol/L (TIR) and glycated haemoglobin (HbA1c). Secondary efficacy outcomes included time above range (TAR10.0, TAR13.9), time below range (TBR3.9, TBR3.0), and coefficient of variability (CV). Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA) risks. Random‐ or fixed‐effects models were used as appropriate.
Results
Four RCTs involving 514 participants were included. The mean age was 32.3 ± 15.7 years, with a mean T1D duration of 14.7 ± 11.1 years, and with mean baseline HbA1c 8.0% ± 1.0%. Three studies compared tubeless HCL with SAP, and one with MDI + CGM. Compared with SC, tubeless HCL improved TIR (MD = 15.31%, 95% CI [7.67%, 22.95%], I 2 = 95%, p < 0.001) and HbA1c (MD = −0.46%, 95% CI [−0.79%, −0.14%], I 2 = 91%, p = 0.005). Lower levels of TAR (TAR10.0, TAR13.9), TBR3.9 and CV were also observed (all p < 0.001) in tubeless HCL group. No significant differences were observed in TBR3.0 (MD = −0.06%, 95% CI [−0.17%, 0.06%], I 2 = 71%, p = 0.35) and insulin dose. DKA and SH events were rare in both groups.
Conclusions
The available evidence suggests that tubeless HCL systems may improve glycaemic control without increasing insulin dose or short‐term safety risks. Head‐to‐head trials using identical algorithms are needed to isolate form‐factor‐specific effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China.
- Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Mengyun Lei, Yongwen Zhou, Ping Ling, Zhe Dai, Jinhua Yan
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
Zitieren
APA
Lei, M., Lin, Q., Zhou, Y., Ni, Y., Lin, Z., Ling, P., Dai, Z., Tang, J., & Yan, J. (2026). Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism, 28(9), 8637-8648. https://doi.org/10.1111/dom.71061
Vancouver
Lei M, Lin Q, Zhou Y, Ni Y, Lin Z, Ling P, et al. Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(9):8637-8648. doi:10.1111/dom.71061
BibTeX
@article{Lei2026,
author = {Lei, Mengyun and Lin, Qiongyan and Zhou, Yongwen and Ni, Ying and Lin, Ziqing and Ling, Ping and Dai, Zhe and Tang, Jun and Yan, Jinhua},
title = {Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {8637--8648},
doi = {10.1111/dom.71061}
}
EUVIMED